Leading The Way With Pathogen Inactivation

Patient health and well-being is why Cerus exists

At Cerus, blood safety is personal because protecting patients’ health and well-being is why we exist. Cerus’ passion to serve all patients requiring safe blood transfusions drives all of us to go the extra mile, to ensure that patients everywhere have access to safe blood in their time of need.

Knowing first-hand the importance of safe blood

When Laurence Corash, MD, Cerus’ founder and Chief Scientific Officer, discovered during his tenure as a physician at UCSF that 300 of his patients had contracted HIV from transfusions, he knew more needed to be done to protect blood supplies from current and future blood-borne pandemic. He devoted the rest of his career to developing an effective way to prevent transfusion transmitted Infections (TTIs).

Blood Matters™

This is our mantra and cornerstone. It is the beating heart of the Cerus culture, constantly reinvigorating our common cause of making safe blood available to those in need. With the INTERCEPT™ Blood System, our robust pathogen inactivation process, we are focused on safeguarding patients by delivering the full complement of reliable products and expertise for transfusion medicine.

Meeting the highest quality standards

Cerus remains the only company in the blood transfusion space to earn both CE Mark and FDA approval for the pathogen inactivation of both platelet and plasma components, and the INTERCEPT™ Blood System has become standard of care in a number of countries globally. The INTERCEPT™ Blood System is EU MDR 2017/745 approved* and is the only U.S. FDA approved pathogen reduction system for platelets and plasma.

* Illuminator and processing sets for platelets and plasma are EU MDR 2017/745 approved and classified as class IIb and III medical devices respectively